HIF-1α expression predicts poor therapeutic response and clinical outcome in human breast cancers [498] and contributes to resistance to the tyrosine kinase inhibitor Lapatinib in ErbB2-positive breast cancer cells [499]. This evidence concerns the gene ERBB2 and breast carcinoma.